Bookmark
Forward
QuickView for Mefenamic acid (compound)
PubChem
| Name: | Mefenamic Acid |
|---|---|
| PubChem Compound ID: | 4044 |
| Description: | A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. |
| Molecular formula: | C15H15NO2 |
| Molecular weight: | 241.285 g/mol |
| Synonyms: |
Benzoic acid, 2-[(2,3-dimethylphenyl)amino]-; Acidum mefenamicum [INN-Latin]; Mefenamic Acid; N-2,3-Xylylanthranilic acid; D00151; Mefenamic acid (JP15/USP); MLS000069709; Bafhameritin-M; KBio2_003222; Mefedolo.
show more » |
DrugBank
Identification
| Name: | Mefenamic Acid |
|---|---|
| Name (isomeric): | DB00784 |
| Drug Type: | small molecule |
| Description: | A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. |
| Synonyms: |
Methenamic Acid; Acide Mefenamique; Mefenacid; Mephenamic Acid; Mefenaminsaeure; Mephenaminic Acid; Mefanamic Acid
|
| Brand: | Bonabol, Vialidon, Parkemed, Pontal, Ponstel, Mefacit, Tanston, Coslan, Ponstil, Namphen, Bafhameritin-M, Lysalgo, In-M, Ponalar, Bafameritin-M, HL 1, Ponstan, Tamany Bonsan, Ponstan Forte, Ponstyl |
| Category: | Cyclooxygenase Inhibitors |
| CAS number: | 61-68-7 |
Pharmacology
| Indication: | For the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever. |
|---|---|
| Pharmacology: | Mefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase. |
| Mechanism of Action: | Mefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced. |
| Absorption: | Mefenamic acid is rapidly absorbed after oral administration. |
| Protein binding: | 90% |
| Biotransformation: | Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly. |
| Route of elimination: | The fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination. |
| Half Life: | 2 hours |
| Clearance: | Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)] |
| Toxicity: | Oral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
